Evolocumab in Primary Prevention." 🧬🛡️🎯 LDL: Down 55%. CV Events: Down 25%.
Dr RR Baliga's "Got Knowledge Doc" Podkast
November 10, 20254m 52s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL.
💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.
🫀 Strong science. Clear signal. A new chapter in preventive cardiology.
#Cardiology #LDL #Prevention #VESALIUSCV